Business Wire

c-LEcta Expands Collaboration With Specialty Medical Logistics Provider World Courier

28.7.2020 10:30:00 EEST | Business Wire | Press release

Share

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development has started working with World Courier, an AmerisourceBergen company. With a presence in 50+ countries, World Courier is driven by a commitment to excellence, and provides customized solutions with global reach to increase access to care; making them a highly trusted specialty logistics company for c-LEcta’s customers in the pharmaceutical industry.

The cooperation focuses on the transport of time-critical and temperature-sensitive products. Transport is carried out in specialized packaging that allows for a secure cold chain and continuous temperature tracking of the valuable enzymes. “The cooperation with World Courier is the right step to further strengthen and expand our logistics chain, particularly in view of our sensitive and valuable products. We not only minimize the risk of transport damages and delays but also enable our customers to check the transport conditions without any gaps. This means we meet even the highest demands of our customers in the pharmaceutical industry with regard to quality and reliability of deliveries,” explains Carsten Fietz, Head of Finance & Administration at c-LEcta. Many audits by renowned international customers from the pharmaceutical industry, all of which have been successfully completed, confirm the importance of a high-quality supply chain.

World Courier specializes in the transport of time and temperature sensitive products for the biopharmaceutical industry, such as the DENARASE product family, for c-LEcta. These products are primarily used in the field of gene and cell therapy, but are also put to use in the production of vaccines. In the general context of the COVID-19 crisis, c-LEcta has seen a significant increase in shipments. “Especially in this difficult time for all of us, the relationship has proven to be very successful and stable. World Courier was able to maintain the international cold chains that are very important for us at all times. Thus, even during the Coronavirus crisis, we were able to deliver our products to our customers worldwide on time,” said Carsten Fietz.

World Courier’s strengths in full-service handling are particularly evident in temperature-controlled deliveries over longer distances and thus over extended periods of time. The collaboration currently focuses on the North American and Asian regions.

About c-LEcta

c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 80 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.

About World Courier

World Courier provides unparalleled specialty logistics services to drive the commercial success of our partners around the globe. For 50 years, we’ve delivered peace of mind through world-class supply chain programs, transportation services, storage of time- and temperature-sensitive products, and innovative, cutting-edge medicines including cell and gene therapies. Through our daily work – and powered by our nearly 3,000 associates – we are united in our responsibility to create healthier futures. With a presence in 50+ countries, World Courier is driven by a commitment to excellence, and provides customized solutions with global reach to increase access to care; making us the most trusted specialty logistics company in the world. Learn more at worldcourier.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

cometis AG
Matthias Kunz
Phone: +49 (0) 611 - 205855 – 64
Fax: +49 (0) 611 - 205855 – 66
e-mail: kunz@cometis.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Expands Omlyclo ® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 01:40:00 EEST | Press release

Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other European countries and plans to complete the rollout across Europe by the end of the year. Celltrion is offering Omlyclo® 300 mg in both pre-filled syringe (PFS) and autoinjector (AI) presentations, allowing patients and healthcare professionals a choice of device depending on the treatment setting and individual patient needs. This comprehensive port

Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 16:13:00 EEST | Press release

Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity verification, we're able to offer unprecedented security, performance, and innovation. Organisations can now accelerate their digital transformation

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 14:02:00 EEST | Press release

SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased precision and control provided by the system help operators optimize reservoir access, improve production performance and maximize recovery. "Operators are asking int

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 14:01:00 EEST | Press release

Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI can reason over. For customers, this means research that surfaces the right authority faster, answers with even clearer reasoning and sources, drafting guided by matter-specific context, and great

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye